The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-β Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice

Tucker, Stina, Möller, Christer, Tegerstedt, Karin, Lord, Anna, Laudon, Hanna, Sjödahl, Johan, Söderberg, Linda, Spens, Erika +6 more·2015·Journal of Alzheimer’s Disease

DOI 10.3233/jad-140741

Cited by (274)

Items 101–200 of 274

Review of Advanced Drug Trials Focusing on the Reduction of Brain Beta-Amyloid to Prevent and Treat Dementia
Boris Decourt, Keith Noorda, Kevin J. Noorda, Jiong Shi, Marwan Noel Sabbagh · 2022 · Journal of Experimental Pharmacology
Structural Dynamics of Amyloid-β Protofibrils and Actions of Anti-Amyloid-β Antibodies as Observed by High-Speed Atomic Force Microscopy
Takahiro Watanabe‐Nakayama, Mayumi Tsuji, Kenichi Umeda, Tatsunori Oguchi, Hiroki Konno, Moeko Noguchi‐Shinohara, Yuji Kiuchi, Noriyuki Kodera, David B. Teplow, Kenjiro Ono · 2023 · Nano Letters
Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research
Eric Edward Smith, Natalie A. Phillips, Howard Feldman, MICHAEL J. BORRIE, Aravind Ganesh, Alexandre Henri‐Bhargava, Philippe Desmarais, Andrew Frank, AmanPreet Badhwar, Laura Barlow et al. · 2025 · The Journal of Prevention of Alzheimer s Disease
Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives
Bruno Pietro Imbimbo, Madia Lozupone, Mark Watling, Francesco Panza · 2020 · Expert Opinion on Investigational Drugs
On the Common Journey of Neural Cells through Ischemic Brain Injury and Alzheimer’s Disease
Ján Kriška, Zuzana Heřmanová, Tomáš Knotek, Jana Turečková, Miroslava Anděrová · 2021 · International Journal of Molecular Sciences
Emerging Alzheimer’s disease therapeutics: promising insights from lipid metabolism and microglia-focused interventions
Nour S. Tobeh, Kimberley D. Bruce · 2023 · Frontiers in Aging Neuroscience
Recent Insights into the Neurobiology of Alzheimer’s Disease and Advanced Treatment Strategies
Kuttiappan Anitha, Mandeep Kumar Singh, Komal Kohat, Talagampala Sri Varshini, Santenna Chenchula, Padmavathi R, Lakshmi Sahitya Amerneni, Vishnu Vardhan K, Mythili Bai K, Madhav Rao Chavan et al. · 2024 · Molecular Neurobiology
Lecanemab: More Questions Than Answers!
Upinder Kaur, Jaideep Reddy, Ashutosh Tiwari, Sasanka Chakrabarti, Sankha Shubhra Chakrabarti · 2023 · Clinical Drug Investigation
Soluble cerebral Aβ protofibrils link Aβ plaque pathology to changes in CSF Aβ42/Aβ40 ratios, neurofilament light and tau in Alzheimer’s disease model mice
Emelie Andersson, Nils Lindblom, Shorena Janelidze, Gemma Salvadó, Eleni Gkanatsiou, Linda Söderberg, Christer Möller, Lars Lannfelt, Junyue Ge, Jörg Hanrieder et al. · 2025 · Nature Aging
Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer’s disease
Chris G. Parsons, Gerhard Rammes · 2017 · Expert Opinion on Investigational Drugs
Ozone: complicated effects in central nervous system diseases
Xu Zhang, Shijun Wang, Si-Cen Wan, Xiang Li, Gang Chen · 2024 · Medical Gas Research
Discovery of a novel pseudo β-hairpin structure of N-truncated amyloid-β for use as a vaccine against Alzheimer’s disease
Preeti Bakrania, Gareth Hall, Yvonne Bouter, Caroline Bouter, Nicola Beindorff, Richard H. Cowan, Sarah L. Davies, Jemma Price, Chido Mpamhanga, Elizabeth A. Love et al. · 2021 · Molecular Psychiatry
Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings
Pallavi Duggal, Sidharth Mehan · 2019 · Journal of Alzheimer s Disease Reports
Amyloid-Related Imaging Abnormalities in the Era of Anti-Amyloid Beta Monoclonal Antibodies for Alzheimer’s Disease: Recent Updates on Clinical and Imaging Features and MRI Monitoring
Jeong, So Yeong, Suh, Chong Hyun, Kim, Sang Joon, Lemere, Cynthia Ann, Lim, Jae-Sung, Lee, Jae-Hong · 2024 · Korean Journal of Radiology
Advances in amyloid-targeting monoclonal antibodies for Alzheimer’s disease: clinical and public health issues
Simone Salemme, Antonio Ancidoni, Nicoletta Locuratolo, Paola Piscopo, Eleonora Lacorte, Marco Canevelli, Nicola Vanacore · 2023 · Expert Review of Neurotherapeutics
Promising candidates from drug clinical trials: Implications for clinical treatment of Alzheimer's disease in China
Cao, Yuxia, Yu, Feng, Lyu, Yi, Lu, Xianfu · 2022 · Frontiers in Neurology
Monoclonal antibodies and aptamers: The future therapeutics for Alzheimer's disease
Alvaro A. Barrera-Ocampo · 2024 · Acta Pharmaceutica Sinica B
Current peptide vaccine and immunotherapy approaches against Alzheimer’s disease
Parrocha, Chelsea Marie T., Nowick, James S. · 2023 · Peptide Science
Blood-derived factors to brain communication in brain diseases
Jiachen He, Yanming Zhang, Yansu Guo, Jiaqi Guo, Xi Chen, Shuaili Xu, Xiaohan Xu, Chuanjie Wu, Chengeng Liu, Jian Chen et al. · 2024 · 中国科学通报：英文版
Experimental modeling of Alzheimer's disease: Translational lessons from cross‐taxon analyses
Konstantin B. Yenkoyan, Maria M. Kotova, Kirill V. Apukhtin, David S. Galstyan, Tamara G. Amstislavskaya, Tatyana V. Strekalova, Murilo S. de Abreu, Vergine A. Chavushyan, Lee Wei Lim, Longen Yang et al. · 2025 · Alzheimer s & Dementia
Amyloid Oligomers, Protofibrils and Fibrils
Mohammad Khursheed Siddiqi, Nabeela Majid, Sadia Malik, Parvez Alam, Rizwan Hasan Khan · 2019 · Sub-cellular biochemistry/Subcellular biochemistry
Amyloid inhibition by molecular chaperones in vitro can be translated to Alzheimer's pathology in vivo
Axel Abelein, Jan Johansson · 2023 · RSC Medicinal Chemistry
Invasive and non-invasive therapies for Alzheimer’s disease and other amyloidosis
Gaurav Pandey, Vibin Ramakrishnan · 2020 · Biophysical Reviews
Cerebrospinal fluid and blood biomarkers in the diagnostic assays of Alzheimer’s disease
Liding Zhang, Xiaohan Liang, Zhihong Zhang, Haiming Luo · 2021 · Journal of Innovative Optical Health Sciences
Low-Dose Delta-9-Tetrahydrocannabinol as Beneficial Treatment for Aged APP/PS1 Mice
Yanhong Wang, Yuzhu Hong, Jiyu Yan, Breanna Brown, Xiaoyang Lin, Xiaolin Zhang, Ning Shen, Minghua Li, Jianfeng Cai, Marcia N. Gordon et al. · 2022 · International Journal of Molecular Sciences
Fluid Biomarkers in Alzheimer’s Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments
Linda Giampietri, Elisabetta Belli, Maria Francesca Beatino, Sara Giannoni, Giovanni Palermo, Nicole Campese, Gloria Tognoni, Gabriele Siciliano, Roberto Ceravolo, Ciro De Luca et al. · 2022 · Diagnostics
Population pharmacokinetics and exposure–response analyses of safety ( ARIA ‐E and isolated ARIA ‐H) of lecanemab in subjects with early Alzheimer's disease
Oneeb Majid, Youfang Cao, Brian A. Willis, Seiichi Hayato, Osamu Takenaka, Bojan B. Lalovic, Sree Harsha Sreerama Reddy, Natasha Penner, Larisa Reyderman, Sanae Yasuda et al. · 2024 · CPT Pharmacometrics & Systems Pharmacology
Potential Mechanisms of Tunneling Nanotube Formation and Their Role in Pathology Spread in Alzheimer’s Disease and Other Proteinopathies
Szymon Kotarba, Marta Kozłowska, Małgorzata Scios, Kamil Saramowicz, Julia Barczuk, Zuzanna Granek, Natalia Siwecka, Wojciech Wiese, Michał Golberg, Grzegorz Galita et al. · 2024 · International Journal of Molecular Sciences
BACE Inhibitor Clinical Trials for Alzheimer’s Disease
Elyse A. Watkins, Robert J. Vassar · 2024 · Journal of Alzheimer s Disease
Targeting soluble amyloid-beta oligomers with a novel nanobody
Justin R. Haynes, Clayton A. Whitmore, William J. Behof, Charlotte A. Landman, Henry H. Ong, Andrew P. Feld, Isabelle C. Suero, Celeste B. Greer, John C. Gore, Printha Wijesinghe et al. · 2024 · Scientific Reports
An Overview of Several Inhibitors for Alzheimer’s Disease: Characterization and Failure
Subramanian Boopathi, Adolfo B. Poma, Ramón Garduño‐Juárez · 2021 · International Journal of Molecular Sciences
Immunotherapy: An emerging treatment option for neurodegenerative diseases
Abhiyanta Mukherjee, Soumojit Biswas, Ipsita Roy · 2024 · Drug Discovery Today
A Rational Structured Epitope Defines a Distinct Subclass of Toxic Amyloid-beta Oligomers
Judith M. Silverman, Ebrima Gibbs, Xubiao Peng, Kris M. Martens, Claudia Balducci, Jing Wang, Masoud Yousefi, Catherine M. Cowan, Guillaume Lamour, Sarah Louadi et al. · 2018 · ACS Chemical Neuroscience
Postulating the possible cellular signalling mechanisms of antibody drug conjugates in Alzheimer's disease
Prashanth Punyakoti, Tapan Behl, Aayush Sehgal, Shivam Yadav, Monika Sachdeva, Md. Khalid Anwer, Celia Bertha Vargas-De-La-Cruz, Thangavel Venkatachalam, Maaz Naqvi, Raman Verma et al. · 2022 · Cellular Signalling
Aβ Oligomer Toxicity-Reducing Therapy for the Prevention of Alzheimer’s Disease: Importance of the Nrf2 and PPARγ Pathways
Wataru Araki · 2023 · Cells
PET Imaging in Preclinical Anti-Aβ Drug Development
Stina Syvänen, Silvio R. Meier, Sahar Roshanbin, Mengfei Xiong, Rebecca Faresjö, Tobias Gustavsson, Gillian Bonvicini, Eva Schlein, Ximena Aguilar, Ulrika H. Julku et al. · 2022 · Pharmaceutical Research
Production of Monoclonal Antibodies to Pathologic β-sheet Oligomeric Conformers in Neurodegenerative Diseases
Fernando Goñi, Mitchell Martá-Ariza, Daniel Kevin Peyser, Krystal Herline, Thomas Wısnıewskı · 2017 · Scientific Reports
Antibodies Raised Against an Aβ Oligomer Mimic Recognize Pathological Features in Alzheimer’s Disease and Associated Amyloid-Disease Brain Tissue
Adam G. Kreutzer, Chelsea Marie T. Parrocha, Sepehr Haerianardakani, Gretchen Guaglianone, Jennifer T. Nguyen, Michelle N. Diab, William H. Yong, Mari A. Perez-Rosendahl, Elizabeth Head, James S. Nowick · 2023 · ACS Central Science
Amyloid-β Clearance with Monoclonal Antibodies: Transforming Alzheimer’s Treatment
Rabab Fatima, Yumna Khan, Mudasir Maqbool, Prasanna Srinivasan Ramalingam, Mohammad Gayoor Khan, Ajay Singh Bisht, Md Sadique Hussain · 2025 · Current Protein and Peptide Science
Lecanemab‐Associated Amyloid‐β Protofibril in Cerebrospinal Fluid Correlates with Biomarkers of Neurodegeneration in Alzheimer's Disease
Moeko Noguchi‐Shinohara, Kazuyoshi Shuta, Hidetomo Murakami, Yukiko Mori, Junji Komatsu, Chizuru Kobayashi, Steven M. Hersch, Kanta Horie, Kenjiro Ono · 2025 · Annals of Neurology
A calcium-sensitive antibody isolates soluble amyloid-β aggregates and fibrils from Alzheimer’s disease brain
Andrew M. Stern, Lei Liu, Shan‐Xue Jin, Wen Liu, Angela L. Meunier, Maria Ericsson, Michael B. Miller, Megan Batson, Tingwan Sun, Sagar V. Kathuria et al. · 2022 · Brain
New Insights into Alzheimer’s Disease: Novel Pathogenesis, Drug Target and Delivery
Haishu Chen, Jinan Xu, Hanyuan Xu, Tiancheng Luo, Yihao Li, Ke Jiang, Yangping Shentu, Zhiqian Tong · 2023 · Pharmaceutics
Immunotherapy Targeting Amyloid-ß Peptides in Alzheimer’s Disease
Silvia Zampar, Oliver Wirths · 2020 · Exon Publications eBooks
Early intervention anti-Aβ immunotherapy attenuates microglial activation without inducing exhaustion at residual plaques
Lis de Weerd, Selina Hummel, Stephan A. Müller, Iñaki Paris, Thomas Sandmann, Marie Eichholtz, Robin Gröger, Amelie L. Englert, Stephan Wagner, Connie Ha et al. · 2025 · Molecular Neurodegeneration
Recent Trends in Active and Passive Immunotherapies of Alzheimer’s Disease
Meshal Alshamrani · 2023 · Antibodies
Critical thinking of Alzheimer’s transgenic mouse model: current research and future perspective
Xinyue Li, Meina Quan, Yiping Wei, Wei Wang, Lingzhi Xu, Qi Wang, Jianping Jia · 2023 · Science China Life Sciences
Failure, Success, and Future Direction of Alzheimer Drugs Targeting Amyloid‐β Cascade: Pros and Cons of Chemical and Biological Modalities
Jimin Kim, Hanna Jeon, Hye Yun Kim, Young Soo Kim · 2023 · ChemBioChem
Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years
Alexandra Wicker, Jahnavi Shriram, Boris Decourt, Marwan Noel Sabbagh · 2024 · Neurology and Therapy
Chimeric antigen receptors discriminate between tau and distinct amyloid-beta species
Cynthia J. Siebrand, Nicholas J. Bergo, Suckwon Lee, Julie Kay Andersen, Chaska C. Walton · 2025 · Journal of Translational Medicine
Disease-modifying drugs for Alzheimer disease: implications for people in Canada
Jennifer Ann Watt, Wanrudee Isaranuwatchai, Linda Grossman, Sharon Elizabeth Straus · 2023 · Canadian Medical Association Journal
Another Use for a Proven Drug: Experimental Evidence for the Potential of Artemisinin and Its Derivatives to Treat Alzheimer’s Disease
Eva Kiss, S. Kins, Karin Gorgas, Kinga Hajnal Venczel Szakács, Joachim Kirsch, J. Kuhse · 2024 · International Journal of Molecular Sciences
Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease
Taha Basit Ameen, Umair Ali, Omme Salma, Muhammad Abdul Samee, Syed Muhammad Iraj Abbas, Syeda Naveera Kashif, Muhammad Arif Arifi, Mashooque Ali, Maher Khowaja, Syed Muhammad Sinaan Ali et al. · 2025 · The Egyptian Journal of Neurology Psychiatry and Neurosurgery
Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease
Marianne von Euler Chelpin, Linda Söderberg, Johanna M. Fälting, Christer Möller, Marco Giorgetti, Radu Constantinescu, Kaj Blennow, Henrik Zetterberg, Kina Höglund · 2020 · Journal of Parkinson s Disease
Insights for Alzheimer's disease pharmacotherapy and current clinical trials
André Luiz Carneiro Soares do Nascimento, Richard Perosa Fernandes, Ana Carina Sobral Carvalho, Isadora Frigieri, Renata Carolina Alves, Marlus Chorilli · 2022 · Neurochemistry International
Limitations of Alzheimer’s Disease Medications
Aslam Ramjan Pathan · 2023 · NeuroPharmac Journal
Repetitive Transcranial Magnetic Stimulation-Mediated Neuroprotection in the 5xFAD Mouse Model of Alzheimer’s Disease Through GABRG2 and SNAP25 Modulation
Jinyang Wang, Chenming Zhou, Zhimin Huang, Xiaoming Ji, Rui Cui, Yunxiao Kang, Guoliang Zhang, Yu Wang, Tianyun Zhang · 2024 · Molecular Neurobiology
Exploring the efficacy and safety of lecanemab in the management of early Alzheimer’s disease: A systematic review of clinical evidence
Rehab Emad Ashmawy, Olalekan John Okesanya, Bonaventure Michael Ukoaka, Faithful Miebaka Daniel, Sonsochukwu Godfrey Ezedigwe, Abdulmajeed Opeyemi Agboola, Mohamed Mustaf Ahmed, Jerico Bautista Ogaya, Blessing Olawunmi Amisu, Olaniyi Abideen Adigun et al. · 2025 · Journal of Alzheimer s Disease
Cholinergic Reinforcement Signaling Is Impaired by Amyloidosis Prior to Its Synaptic Loss
Simon Allard, Marshall G. Hussain Shuler · 2023 · Journal of Neuroscience
Recent Updates on the Development of Therapeutics for the Targeted Treatment of Alzheimer’s Disease
Shivam Rajput, Rishabha Malviya, Shiv Bahadur, Dinesh Puri · 2023 · Current Pharmaceutical Design
Advances in Understanding and Managing Alzheimer's Disease: From Pathophysiology to Innovative Therapeutic Strategies
Sunny Rathee, Debasis Sen, Vishal Pandey, Sanjay Jain · 2024 · Current Drug Targets
Proteolytic therapeutic modalities for amyloidoses: Insights into immunotherapy, PROTAC, and photo-oxygenation
Mai Kuriyama, Chu Fan Wang, Tatsuya Nagase, Youhei Sohma, Motomu Kanai, Yukiko Hori, Taisuke Tomita · 2025 · Neurotherapeutics
A review of drugs for treatment of Alzheimer’s disease in clinical trials: main trends
Сергей Олегович Бачурин · 2016 · S S Korsakov Journal of Neurology and Psychiatry
Neuroprotective Potential of Raloxifene via G-Protein-Coupled Estrogen Receptors in Aβ-Oligomer-Induced Neuronal Injury
Tetsuhito Nohara, Mayumi Tsuji, Tatsunori Oguchi, Yutaro Momma, Hideaki Ohashi, Miki Nagata, Naohito Ito, Ken Yamamoto, Hidetomo Murakami, Yuji Kiuchi · 2023 · Biomedicines
Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns
Daoran Lu, Fangzhou Dou, Jianjun Gao · 2023 · Drug Discoveries & Therapeutics
Targeting protein misfolding in Alzheimer’s disease: The emerging role of molecular chaperones
Anushka Sharma, Shriyansh Srivastava, Pranav Gupta, Sathvik Belagodu Sridhar, M. Tariq, GSN Koteswara Rao, Sachin Kumar, Tabarak Malik · 2025 · Biomedicine & Pharmacotherapy
Alzheimer's Targeted Treatments: Focus on Amyloid and Inflammation
Takeshi Iwatsubo, Michael C. Irizarry, Joseph W. Lewcock, María C. Carrillo · 2023 · Journal of Neuroscience
A light at the end of the tunnel – from mutation identification to a potential treatment for Alzheimer’s disease
Lars Lannfelt · 2023 · Upsala Journal of Medical Sciences
Disease modifying effects of the amyloid-beta protofibril-selective antibody mAb158 in aged Tg2576 transgenic mice
Biljana Rizoska, Olof Zachrisson, Paulina Appelkvist, Emma Boström, My Björklund, Adeline Rachalski, Eleni Gkanatsiou, Helen Kylefjord, Linda Söderberg, Patrik Nygren et al. · 2024 · Molecular and Cellular Neuroscience
Single-domain antibodies and aptamers drive new opportunities for neurodegenerative disease research
Rachel L. Shoemaker, Roxanne J. Larsen, Peter A. Larsen · 2024 · Frontiers in Immunology
Current Trends in the Development of Drugs for the Treatment of Alzheimer’s Disease and their Clinical Trials
Сергей Олегович Бачурин, E.V. Bovina, A. A. Ustyugov · 2018 · Biomedical Chemistry Research and Methods
Antibody engagement with amyloid‐beta does not inhibit [ 11 C]PiB binding for PET imaging
Mengfei Xiong, Amelia D. Dahlén, Sahar Roshanbin, Elin Wik, Ximena Aguilar, Jonas Eriksson, Dag Sehlin, Stina Syvänen · 2024 · Journal of Neurochemistry
Amyloid-Directed Antibodies: Past, Present, and Future
Keith Noorda, Kevin J. Noorda, Marwan N. Sabbagh, John A. Bertelson, Jonathan Singer, Boris Decourt · 2024 · Journal of Alzheimer s Disease
Perspectives on drug discovery strategies based on IDPs
Gustavo Fuertes, Laura Nevola, Santi Esteban-Martín · 2019 · Elsevier eBooks
In vivo characterization of cerebrovascular impairment induced by amyloid β peptide overload in glymphatic clearance system using swept-source optical coherence tomography
Yao Yu, Ning Zhang, Ben Xiang, Ning Ding, Jian Liu, Jiangmei Huang, Min Zhao, Yuqian Zhao, Yi Wang, Zhenhe Ma · 2023 · Neurophotonics
Targeting cerebral diseases with enhanced delivery of therapeutic proteins across the blood-brain barrier
Yanning Bao, Weiyue Lu · 2023 · Expert Opinion on Drug Delivery
Recent advances in Alzheimer’s disease pathogenesis and therapeutics from an immune perspective
Thai-Duong Nguyen, Loi Nguyen Dang, Jung-hee Jang, Soyeun Park · 2023 · Journal of Pharmaceutical Investigation
Strategies Targeting Soluble β-Amyloid Oligomers and their Application to Early Diagnosis of Alzheimer’s Disease
Fantian Zeng, Yuyan Li, Yungen Xu, Jian Yang, Zhengshi Liu, Xiaofang Li, Longfei Ren · 2019 · Current Alzheimer Research
Temporal Characterization of the Amyloidogenic APPswe/PS1dE9;hAPOE4 Mouse Model of Alzheimer’s Disease
Martine B. Grenon, Maria-Tzousi Papavergi, Praveen Bathini, Martin J. Sadowski, Cynthia Ann Lemere · 2024 · International Journal of Molecular Sciences
CD22 modulation alleviates amyloid β-induced neuroinflammation
Yu Dong Mai, Qingqing Zhang, Cheuk Lim Fung, Shui On Leung, Chi Ho Chong · 2025 · Journal of Neuroinflammation
Crossing Barriers: Advancements in Macromolecular Therapeutics for Neurodegenerative Diseases and Strategies to Overcome the Blood–Brain Barrier
Bekas Alo, Christina Lamers · 2025 · ACS Pharmacology & Translational Science
Multiple ischemic strokes in a patient treated with Lecanemab: a case report
Hajar Alammar, Mamadou Diallo, Daniel A. Llano · 2025 · Neurocase
Lecanemab appropriate use recommendations for clinical practice in the UK
Catherine Jane Mummery, Jill Rasmussen, Daniel J. Blackburn, Elizabeth Jane Coulthard, Rhys Davies, Rachel Dorsey, Nick C. Fox, Akram A. Hosseini, Chineze Ivenso, Matthew S. Jones et al. · 2025 · Journal of Neurology Neurosurgery & Psychiatry
Functional nanoassemblies for the diagnosis and therapy of Alzheimer's diseases
Lingxiao Zhang, Heng Sun, Ying Chen, Min Wei, Jiyoung Lee, Fangyuan Li, Daishun Ling · 2021 · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology
Mouse models of Anti-Aβ immunotherapies
Philip Pikus, Raymond Scott Turner, George William Rebeck · 2025 · Molecular Neurodegeneration
Real—world application of lecanemab in early—stage alzheimer's disease: a single—center prospective cohort analysis
Jia Shang, Siyan Zhong, Li Shang, Qingze Zeng, Shuai Zhao, Xiao Luo, Kaicheng Li, Xinyi Zhang, Peiyu Huang, Yaping Yan et al. · 2025 · Alzheimer s Research & Therapy
The glymphatic system as a brain scavenger in Alzheimer’s disease: mechanisms and therapeutic implications
Manyv Zheng, Wenya Su, Luyao Tian, Wenyuan Gao · 2026 · Brain Research
Interim analysis of all-case post-marketing surveillance study in Japan: lecanemab in patients with early Alzheimer’s disease
Atsushi Iwata, Yukinori Sakata, Kinuyo Koizumi, Akira Endo, Weijie Kuang, Kenta Sumitomo, Mika Ishii · 2026 · The Journal of Prevention of Alzheimer s Disease
How will the emergence of lecanemab change dementia treatment?
Atsushi Iwata · 2024 · Geriatrics and gerontology international/Geriatrics & gerontology international
Clinical Management in Alzheimer’s Disease in the Era of Disease-Modifying Therapies
Michael H. Guo, Sanjeev Vaishnavi · 2023 · Current Treatment Options in Neurology
The Curcumin Derivative GT863 Protects Cell Membranes in Cytotoxicity by Aβ Oligomers
Yutaro Momma, Mayumi Tsuji, Tatsunori Oguchi, Hideaki Ohashi, Tetsuhito Nohara, Naohito Ito, Ken Yamamoto, Miki Nagata, Atsushi Kimura, Shiro Nakamura et al. · 2023 · International Journal of Molecular Sciences
Atsttrin reduces lipopolysaccharide-induced neuroinflammation by inhibiting the nuclear factor kappa B signaling pathway
Meng Si, Lei Cheng, Lian Liu, Yuan Qu, Yi Fan Liu, Hua Zhao, Hecheng Ma, AhmedFayyaz Noor, Chang-Jiao Ji, Lin Nie · 2019 · Neural Regeneration Research
Photodynamic and Photothermal Therapies using Nanotechnology Approach in Alzheimer's Disease
Busra Ozturk, Huriye Demir, Mine Silindir‐Gunay, Yağmur Akdağ, Selma Şahin, Tuğba Gülsün · 2025 · Current Neuropharmacology
Conformational inhibitors of protein aggregation
María del Carmen Fernández‐Ramírez, Shumaila Afrin, Lorena Saelices · 2023 · Current Opinion in Structural Biology
An update on emerging anti-amyloid-β monoclonal antibodies for treating Alzheimer’s disease: the role of apolipoprotein E
Madia Lozupone, Vittorio Dibello, Antonio Daniele, Francesco Panza · 2025 · Expert Opinion on Emerging Drugs
Natural product-based strategies targeting inflammation in Alzheimer's disease: Mechanisms, drug delivery, and clinical trials
Gaoshuang Fu, Mingmin Pan, Qingling Sun, Guangxin Yue, Tong Lei · 2025 · Journal of Pharmaceutical Analysis
Microglial, astrocytic, oligodendrocyte, B-/T-cell and neutrophil dysregulation in neuroinflammation of Alzheimer's disease and related dementias
Asem Surindro Singh, Afsar Raza Naqvi, Machathoibi Takhellambam Chanu · 2026 · Journal of Psychiatric Research
Identification of fibrinogen as a plasma protein binding partner for lecanemab biosimilar IgG
Jean‐Pierre Bellier, Andrea M. Román Viera, Caitlyn Christiano, Juliana A. U. Anzai, Stephanie Moreno, Emily C. Campbell, Lucas Godwin, Amy Li, Alan Y. Chen, Sarah M. Alam et al. · 2024 · Annals of Clinical and Translational Neurology
Modeling Alzheimer's disease using cerebral organoids: Current challenges and prospects
Ayodeji Zabdiel Abijo, S Olatunji, Stephen Taiye Adelodun, Moses Oluwasegun Asamu, Noah Adavize Omeiza · 2024 · Brain Organoid and Systems Neuroscience Journal
Passive Immunotherapy in Alzheimer’s Disease
Philip J. Dolan, Wagner M. Zago · 2018 · InTech eBooks
Immunotherapeutic Approaches for the Treatment of Neurodegenerative Diseases: Challenges and Outcomes
Amal Chandra Mondal, Sushma · 2021 · CNS & Neurological Disorders - Drug Targets